Visit-to-Visit Variability of Systolic Blood Pressure and Cardiovascular Disease

Current Hypertension Reports

Volumn 17, Issue 4, 2015, Pages

  Hussein, Wael F ^a   Chang, Tara I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypertension; Kidney; Visit to visit blood pressure variability

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE VARIABILITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; HEALTH SERVICE; HEREDITY; HIGH RISK POPULATION; HUMAN; METRIC SYSTEM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; REVIEW; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; VISIT TO VISIT VARIABLITY; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HYPERTENSION; PATHOPHYSIOLOGY; PHYSIOLOGY; PROGNOSIS; STROKE;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; HUMANS; HYPERTENSION; PROGNOSIS; STROKE;

EID: 84924678467     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-014-0527-8     Document Type: Review

References (55)

1. Pickering TG et al. Recommendations for blood pressure measurement in humans and experimental animals: part 1: blood pressure measurement in humans: a statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45(1):142–61.
2. Muntner P et al. Reproducibility of visit-to-visit variability of blood pressure measured as part of routine clinical care. J Hypertens. 2011;29(12):2332–8.
3. Franklin SS et al. Does the relation of blood pressure to coronary heart disease risk change with aging?: the Framingham Heart Study. Circulation. 2001;103(9):1245–9.
4. Portaluppi F et al. Circadian rhythms and cardiovascular health. Sleep Med Rev. 2012;16(2):151–66.
5. Rothwell PM. Limitations of the usual blood-pressure hypothesis and importance of variability, instability, and episodic hypertension. Lancet. 2010;375(9718):938–48.
6. Mena L et al. A reliable index for the prognostic significance of blood pressure variability. J Hypertens. 2005;23(3):505–11.
7. Rothwell PM et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895–905.
8. Mancia G et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;40:299–305.
9. Diaz, K.M., et al., Visit-to-visit variability of blood pressure and cardiovascular disease and all-cause mortality: a systematic review and meta-analysis. Hypertension, 2014. Comprehensive systematic review of VVV of BP, with focus on differences in metrics and definitions used across studies. Highlights the need for standardized approaches when defining and calculating VVV: BP measurement protocol, number of visits, interval between visits and metrics used.
10. Chang TI et al. Visit-to-visit systolic blood pressure variability and outcomes in hemodialysis. J Hum Hypertens. 2014;28(1):18–24.
11. Gao S et al. Redefined blood pressure variability measure and its association with mortality in elderly primary care patients. Hypertension. 2014;64(1):45–52.
12. Lau KK et al. Visit-to-visit systolic blood pressure variability predicts all-cause and cardiovascular mortality after lacunar infarct. Eur J Neurol. 2014;21(2):319–25.
13. Hsieh YT et al. Visit-to-visit variability in blood pressure strongly predicts all-cause mortality in patients with type 2 diabetes: a 5.5-year prospective analysis. Eur J Clin Invest. 2012;42(3):245–53.
14. Muntner P et al. The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension. 2011;57(2):160–6.
15. Nagai M et al. Visit-to-visit blood pressure variability in the elderly: associations with cognitive impairment and carotid artery remodeling. Atherosclerosis. 2014;233(1):19–26.
16. Lau KK et al. Visit-to-visit blood pressure variability as a prognostic marker in patients with cardiovascular and cerebrovascular diseases–relationships and comparisons with vascular markers of atherosclerosis. Atherosclerosis. 2014;235(1):230–5.
17. Levitan EB et al. Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich). 2012;14(11):744–50.
18. Asayama K et al. Home blood pressure variability as cardiovascular risk factor in the population of Ohasama. Hypertension. 2013;61(1):61–9.
19. Di Iorio B et al. Blood pressure variability and outcomes in chronic kidney disease. Nephrol Dial Transplant. 2012;27(12):4404–10.
20. Hata J et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. Circulation. 2013;128(12):1325–34.
21. Mancia G et al. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis/Clinical Perspective. Circulation. 2012;126(5):569–78.
22. Okada H et al. Visit-to-visit blood pressure variability is a novel risk factor for the development and progression of diabetic nephropathy in patients with type 2 diabetes. Diabetes Care. 2013;36(7):1908–12.
23. Di Iorio B et al. Variability of blood pressure in dialysis patients: a new marker of cardiovascular risk. J Nephrol. 2013;26(1):173–82.
24. Kawai, T., et al., The impact of visit-to-visit variability in blood pressure on renal function. Hypertens Res, 2011.
25. Hastie CE et al. Long-term and ultra long-term blood pressure variability during follow-up and mortality in 14,522 patients with hypertension. Hypertension. 2013;62(4):698–705.
26. Okada H et al. Visit-to-visit variability in systolic blood pressure is correlated with diabetic nephropathy and atherosclerosis in patients with type 2 diabetes. Atherosclerosis. 2012;220(1):155–9.
27. Okada H et al. Visit-to-visit variability in systolic blood pressure is a novel risk factor for the progression of coronary artery calcification. Hypertens Res. 2013;36(11):996–9.
28. Masugata H et al. Visit-to-visit variability in blood pressure over a 1-year period is a marker of left ventricular diastolic dysfunction in treated hypertensive patients. Hypertens Res. 2011;34(7):846–50.
29. Nguyen NT et al. Association of hypertension, diabetes, dyslipidemia, and metabolic syndrome with obesity: findings from the National Health and Nutrition Examination Survey, 1999 to 2004. J Am Coll Surg. 2008;207(6):928–34.
30. McMullan CJ et al. Association of BP variability with mortality among African Americans with CKD. Clin J Am Soc Nephrol. 2013;8(5):731–8.
31. Faramawi MF et al. Metabolic syndrome is associated with visit-to-visit systolic blood pressure variability in the US adults. Hypertens Res. 2014;37(9):875–9.
32. U.S. Renal Data System, USRDS 2013 Annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States, NIDDK, National Institutes of Health, Editor 2013: Bethesda, MD.
33. McMullan, C.J., et al., Visit-to-visit variability in blood pressure and kidney and cardiovascular outcomes in patients with type 2 diabetes and nephropathy: a post hoc analysis from the RENAAL study and the Irbesartan Diabetic Nephropathy Trial. Am J Kidney Dis, 2014.
34. Mallamaci F et al. Long-term visit-to-visit office blood pressure variability increases the risk of adverse cardiovascular outcomes in patients with chronic kidney disease. Kidney Int. 2013;84(2):381–9.
35. Selvarajah V et al. Pre-dialysis systolic blood pressure-variability is independently associated with all-cause mortality in incident haemodialysis patients. PLoS ONE. 2014;9(1):e86514.
36. Shafi, T., et al., Predialysis systolic BP variability and outcomes in hemodialysis patients. Journal of the American Society of Nephrology, 2014.
37. Rossignol P et al. Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL. Hypertension. 2012;60(2):339–46.
38. Yadav S et al. Genome-wide analysis of blood pressure variability and ischemic stroke. Stroke. 2013;44(10):2703–9.
39. Menni C et al. Heritability analyses show visit-to-visit blood pressure variability reflects different pathological phenotypes in younger and older adults: evidence from UK twins. J Hypertens. 2013;31(12):2356–61.
40. Diaz KM et al. Relationship of visit-to-visit and ambulatory blood pressure variability to vascular function in African Americans. Hypertens Res. 2012;35(1):55–61.
41. Rothwell PM et al. Effects of β blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010;9(5):469–80.
42. Shimbo D et al. Association between annual visit-to-visit blood pressure variability and stroke in postmenopausal women: data from the Women’s Health Initiative. Hypertension. 2012;60(3):625–30.
43. Chowdhury EK et al. Systolic blood pressure variability is an important predictor of cardiovascular outcomes in elderly hypertensive patients. J Hypertens. 2014;32(3):525–33.
44. Suchy-Dicey AM et al. Blood pressure variability and the risk of all-cause mortality, incident myocardial infarction, and incident stroke in the cardiovascular health study. Am J Hypertens. 2013;26(10):1210–7.
45. Lau, K.K., et al., Long-term prognostic implications of visit-to-visit blood pressure variability in patients with ischemic stroke. Am J Hypertens, 2014.
46. Kostis JB et al. Visit-to-visit blood pressure variability and cardiovascular death in the systolic hypertension in the elderly program. J Clin Hypertens (Greenwich). 2014;16(1):34–40.
47. Blacher, J., et al., Blood pressure variability: cardiovascular risk integrator or independent risk factor? J Hum Hypertens, 2014.
48. Echt DS et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. N Engl J Med. 1991;324(12):781–8.
49. Muntner P et al. Association between antihypertensive medication adherence and visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich). 2013;15(2):112–7. One of the few studies to examine the association between VVV of BP and adherence to antihypertensive therapy. Used data from a large managed care organization on 1391 patients with hypertension to show that a significant degree of variability existed even among patients with high degree of medication adherence. Poor adherence was associated with higher VVV of BP, but only a small proportion of the variability was explained by non-adherence to BP medications.
50. Diaz KM et al. The effects of weight loss and salt reduction on visit-to-visit blood pressure variability: results from a multicenter randomized controlled trial. J Hypertens. 2014;32(4):840–8.
51. Webb AJ et al. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke: a systematic review and meta-analysis. Lancet. 2010;375(9718):906–15.
52. Muntner P et al. Effect of chlorthalidone, amlodipine, and lisinopril on visit-to-visit variability of blood pressure: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2014;16(5):323–30.
53. Mancia G et al. Visit-to-visit blood pressure variability in the European Lacidipine Study on Atherosclerosis: methodological aspects and effects of antihypertensive treatment. J Hypertens. 2012;30(6):1241–51.
54. Wang JG, Yan P, Jeffers BW. Effects of amlodipine and other classes of antihypertensive drugs on long-term blood pressure variability: evidence from randomized controlled trials. J Am Soc Hypertens. 2014;8(5):340–9. Meta-analysis that analyzed the association of antihypertensive class with VVV of BP using individual data from 47,558 patients from five studies. Study showed that amlodipine (versus all active comparators) associated with of −1.23 mmHg (p = 0.008) lower VVV of BP (measured as standard deviation).
55. Smith TR et al. Medication class effects on visit-to-visit variability of blood pressure measurements: analysis of electronic health record data in the “real world”. J Clin Hypertens (Greenwich). 2013;15(9):655–62.